Page last updated: 2024-12-08
azobenzenearsonate-n-acetyl-l-tyrosine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
N-acetyltyrosine-4-azobenzenearsonic acid : An L-tyrosine derivative having an N(alpha)-acetyl substituent and a 4-arsonophenyldiazenyl group at the 3-position of the benzene ring. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 162400 |
CHEBI ID | 53741 |
MeSH ID | M0040303 |
Synonyms (16)
Synonym |
---|
aba-nat |
aba-l-tyrosine |
39927-13-4 |
azobenzenearsonate-n-acetyl-l-tyrosine |
CHEBI:53741 , |
n-acetyl-3-[(4-arsonophenyl)diazenyl]-l-tyrosine |
mono-azobenzenearsonate-n-acetyl-l-tyrosine |
n-acetyltyrosine-4-azobenzenearsonic acid |
aba-l-tyr |
n-acetyltyrosine-4-azobenzenearsonate-l-tyrosine |
aba-tyr |
l-tyrosine, n-acetyl-3-((4-arsonophenyl)azo)- |
EPITOPE ID:115578 |
Q27124183 |
n-acetyl-3-[(4-arsonophenyl)azo]-l-tyrosine |
DTXSID001252020 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (16)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 15 (93.75) | 18.7374 |
1990's | 1 (6.25) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.43
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.43) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 16 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |